Chuangmo Biotech Secures Tens of Millions in RMB Financing to Advance Dual-Humanized Models and Clinical-Mimetic Preclinical Research Platform

VCBeat has learned that the CRO service provider for pharmacodynamic evaluation of oncology and tumor immunotherapy drugsChuangmo Biotechnology (Beijing) Co., Ltd., successfully completed again after a one-year intervalTens of Millions of RMB in Financing, this round of financing was led byZhongguancun Co-Innovation FundLead Investor,ZBJL CAPITALCo-investment. The funds raised in this round will be primarily used to support the construction of new laboratory facilities, as well as the research and development and establishment of a new preclinical research platform.

Chuangmo Biotechnology (Beijing) Co., Ltd.(hereinafter referred to as "Chuangmo Bio") was established in 2020. The team has built a comprehensive preclinical CRO service platform and developed highly distinctive model platforms, including second-generation humanized immune system models, second-generation patient-derived xenograft (PDX) models, and dual-humanized PDX models suitable for the evaluation of immunotherapies. Since its inception, the company has experienced rapid business growth, initially established a stable customer base, gained recognition from multiple leading enterprise clients, and is currently in a phase of high-speed development.

Amid the industry-wide “winter” in new drug development, Chuangmo Biology remains a highly sought-after target for investors. This is not only due to its rapid revenue growth and expansion, but also because of its unique insights into preclinical research platforms, having established distinctive and competitive dual-humanized mouse models and a biomimetic clinical research platform built upon them.

Tumor immunotherapy is a new generation of cancer treatment that has rapidly developed following traditional therapies such as surgery, radiotherapy, and chemotherapy. Unlike conventional approaches that rely on external forces to kill tumor cells, tumor immunotherapy works by modulating the patient’s own immune system, enabling immune cells to more effectively identify and destroy tumor cells. With significant potential for clinical application, it represents the mainstream direction in the current development of cancer treatment. Immunotherapies exemplified by PD-1 checkpoint inhibitors and adoptive cell therapies such as CAR-T have demonstrated remarkable efficacy in extensive clinical practice, making tumor immunotherapy a key focus of global anti-cancer drug research and development.

However, the high failure rate of clinical trials in the development of novel anti-tumor drugs remains a persistent challenge. The primary reason is that current preclinical drug evaluation platforms fail to comprehensively reflect and assess drug responses in clinical settings. This challenge is particularly acute in cancer immunotherapy research, partly because the inclusion of the immune system increases model complexity by an order of magnitude, and partly because tumor immunology is still a relatively nascent field. While numerous new technologies and therapies are emerging rapidly, the development of preclinical evaluation models has not kept pace. Therefore, constructing experimental animal models that more closely mimic clinical conditions—specifically by simulating the interactions between human tumor cells and the immune system—and selecting appropriate animal models capable of more accurately predicting clinical outcomes have become critical components of cancer immunotherapy research.

In response to this market pain point and demand, Chuangmo Biology has proposed a novel approach: “Bridging the vast “gap” between experimental animal models and humans is key to effectively reducing costs and improving success rates in clinical trials from the very outset!”

Targeting the evaluation needs for novel oncology drug development, Chuangmo Bio has continuously iterated its preclinical research platform and has now established a uniqueSecond-Generation Humanized PBMC Immune System ModelandSecond-Generation PDX Patient-Derived Xenograft ModelCompared with traditional PBMC models, Chuangmo Biotech’s second-generation PBMC model not only overcomes the limitation of reconstructing only T cells but also enables the reconstitution of multiple immune cell types, including T cells, NK cells, and dendritic cells (DCs). The level of immune cell reconstitution is more than 10-fold higher than that achieved with conventional approaches, reaching clinically relevant levels observed in humans, while the modeling success rate has increased from 30–50% to 80–90%. Furthermore, compared with traditional protocols, Chuangmo Biotech’s second-generation PDX model more than doubles model stability, improves experimental efficiency by over 50%, and significantly reduces model costs.

Building on this foundation, Chuangmo Biology has pioneered the integration of PBMC and PDX models in the industry, becoming the first globally to develop a practical, dual-humanized PBMC-PDX model for tumor immunology research. This model enables the reconstruction of human immune systems and tumors at both cellular and tissue levels within mice. It offers high versatility, supporting nearly all types of tumor immunotherapies, while retaining the key advantage of PDX models: high clinical concordance.

Amid the current landscape of flourishing innovation in China’s pharmaceutical industry, Chuangmo Biosciences recognizes the substantial potential demand for model versatility within preclinical research platforms. With this round of financing, Chuangmo Biosciences will continue to advance the performance iteration of its dual-humanized models in tumor immunology, enhance platform versatility by improving information capacity and adaptability, and thereby provide better services to innovative drug development enterprises.

Regarding this round of financing,Dr. Liu Jin, Chairman of Chuangmo BioStatement: Chuangmo Bio sincerely appreciates the strong recognition from both new and existing investors of our endeavors. Amid the current “winter” facing the overall new drug R&D industry, the entire sector is undergoing significant transformation and confronting substantial challenges. We firmly believe that opportunities emerge from these challenges. Chuangmo Bio will continue to align closely with researchers’ needs, provide more powerful tools for new drug development, and remove obstacles on the path of R&D. Chuangmo Bio has established clear horizontal and vertical development goals.Horizontally, Chuangmo Bio will continue to leverage its current technical advantages in immune system animal models to establish a wider variety of disease-specific models, thereby expanding the scope of services supported by its CRO platform. Vertically, the company will continue to capitalize on the high clinical translatability of its existing models to extend its service value chain upstream and downstream, helping new drug developers bridge the gap between preclinical and clinical stages.The support provided by our investors in this financing round will enable Chuangmo Bio to advance more rapidly and further. We are committed to doing our utmost to contribute to the development of new drug R&D in China.

Zhongguancun Co-Innovation Fund：

Chuangmo Bio has assembled a team of experts specializing in preclinical efficacy evaluation, with its core team boasting over a decade of deep industry experience dedicated to resolving critical bottlenecks in research models. As oncology and tumor immunotherapies become the primary focus of future R&D, Chuangmo has carved out a differentiated path in the niche segment of preclinical CRO services, leveraging its stable and rapid modeling capabilities along with its proprietary dual-humanized mouse models. We strongly endorse this differentiated development strategy and are honored to participate in jointly advancing the progress of China’s biopharmaceutical CRO industry.

ZBJL CAPITAL：

Current tumor immunotherapy is a hot research direction, and the role of animal models in reducing costs and front-loading risks in drug development is becoming increasingly prominent. Building an evaluation platform with high clinical predictability and universal target specificity to more realistically and accurately simulate the immune status and tumor microenvironment in clinical patients is the common expectation of anti-tumor drug developers at this stage. Chuangmo Biology, with its innovative dual-humanized experimental animal models, globally leading technology, stable high-quality products, and strict experimental processes, conducts preclinical R&D evaluations of new drugs in a manner that mimics clinical settings. It provides pharmacodynamic data close to clinical efficacy responses for domestic and international new drug developers, supports early pipeline strategy formulation and clinical protocol optimization, improves the success rate of drug development, and holds significant importance for the advancement of innovative drugs.

The Chuangmo Bio team was founded by former scientists from Novo Nordisk and CrownBio. The team possesses extensive experience in establishing PDX models, tumor immunology, CRO services, and translational medicine. With a stable team, strong execution capabilities, and high efficiency and professionalism, it has received widespread acclaim from clients. Within just one and a half years since its establishment, the company has achieved annual revenue exceeding RMB 10 million, demonstrating rapid business growth. It has built an initial customer base and gained recognition from multiple leading enterprises. Currently in a phase of rapid development, the company faces a high market ceiling and is poised to become a leading player in the tumor immunology CRO sector. This round of financing will accelerate the construction of new laboratory facilities, expand production capacity, and enhance the development and construction of new models. By leveraging its unique proprietary platforms to accelerate market expansion, the company aims to support the R&D of novel tumor immunology drugs.

Beijing Zhongguancun Co-Innovative Fund Management Co., Ltd. (hereinafter referred to as “Zhongguancun Co-Innovative Fund”) is a subsidiary controlled by Zhongguancun Development Group. The company manages 12 funds with a total scale exceeding RMB 5 billion, committed to serving national strategies such as the “Coordinated Development of the Beijing-Tianjin-Hebei Region,” the “Belt and Road Initiative,” the “Greater Bay Area,” and the “Integrated Development of the Yangtze River Delta.” It focuses primarily on four hard-tech sectors: next-generation information technology, high-end manufacturing, healthcare, and energy conservation and environmental protection.

ZBJL CAPITAL (Beijing) Investment Management Co., Ltd. (hereinafter referred to as “ZBJL CAPITAL”) is a private equity investment firm established in 2013, with a primary focus on next-generation information technology, biopharmaceuticals, and new energy. Adhering to the investment philosophy of “being grounded in technology and delivering value,” ZBJL CAPITAL emphasizes technological innovation and human health, actively seeking out promising companies with the potential to become industry leaders in the hard-tech sector. By providing support through both capital and resources, the firm aims to empower the growth of Chinese technology enterprises, create value, and benefit humanity and society. In its strategically prioritized biopharmaceutical sector, ZBJL CAPITAL places greater emphasis on genuine innovation and significant clinical relevance, avoiding herd mentality and blind following, while continuously identifying potential unicorn companies with high technical barriers and strong core competitiveness.